A phase II, multi-centre, two-part study to evaluate the safety and efficacy of study drug [V 10153] in acute ischaemic stroke.

Trial Profile

A phase II, multi-centre, two-part study to evaluate the safety and efficacy of study drug [V 10153] in acute ischaemic stroke.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Dec 2015

At a glance

  • Drugs Troplasminogen alfa (Primary)
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VASST
  • Sponsors Vernalis
  • Most Recent Events

    • 09 Dec 2015 Treatment arms changed from 1 to 5, Study design changed to Non-randomized as reported by ClinicalTrials.gov.
    • 24 Mar 2009 Patient numbers amended from 80 to 49 as reported by ClinicalTrials.gov.
    • 24 Mar 2009 End date added from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top